

## UK launch for Mylan, Biocon insulin glargine biosimilar Semglee

14th November 2018



by

[Selina McKee](#)

Mylan and Biocon have announced the UK launch of Semglee - an approved biosimilar of reference medicine insulin glargine.

Semglee is a once-daily, long-acting basal insulin indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

Around one in 17 people in the UK are thought to have diabetes, and the NHS currently spends around 10% of its entire budget on managing the disease, highlighting the huge drain on healthcare resources it presents.

"This has led to a growing need for more affordable treatment options for healthcare providers (HCPs) and their patients, to improve access to a broader range of treatment options for diabetes sufferers, which is critical to managing this growing healthcare challenge," the firms note.

"Insulin glargine biosimilars play a key role in the challenges faced by the NHS and offer a better value option by being able to deliver increased affordability compared with the originator insulin glargine while still offering comparable safety, efficacy and tolerability," noted Mylan UK country manager, Jean-Yves Brault.



### Contact details

---

PharmaTimes Media Ltd.  
Mansard House  
Church Road  
Little Bookham  
Leatherhead  
Surrey KT23 3JG

E: [editorial@pharmatimes.com](mailto:editorial@pharmatimes.com)  
E: [subscriptions@pharmatimes.com](mailto:subscriptions@pharmatimes.com)  
T: +44 (0)20 7240 6999  
F: +44 (0)20 7240 4479



---

© Copyright PharmaTimes Media Limited 2018